Overview
This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.
Eligibility
Inclusion Criteria:
- Recently diagnosed TGCT
- Patients with histologically or clinically confirmed germ cell tumor.
- Age > 18 years of age.
- Anticipated treatment with multicycle (> 2 cycles) / multiagent chemotherapy
- Within 4 weeks of starting C1D1 chemotherapy
- Signed informed consent
- Long-term survivors
- Age > 18 years of age
- Patients with histologically or clinically confirmed germ cell tumor.
- Completed treatment for germ cell tumor with multicycle (> 2 cycles) / multiagent chemotherapy.
- Within years 1-5 of surveillance since Day 1 of last cycle of chemotherapy
- Signed informed consent
Exclusion Criteria:
- Recently diagnosed TGCT
- Patients planned to receive <2 cycles of chemotherapy
- Starting chemotherapy greater than 4 weeks after signing consent and completing initial survey.
- Starting chemotherapy prior to consenting and completing initial survey.
- Long-term survivors
- Patients undergoing active chemotherapy
- Patients who did not complete 1st line chemotherapy.